Tuftsin and its receptor system
Tuftsin is an endogenous tetrapeptide (Thr-Lys-Pro-Arg) released by enzymatic cleavage of the Fc region of immunoglobulin G. It was originally characterised for its phagocyte-activating activity — enhancing macrophage and neutrophil function through binding to a specific receptor system historically labelled as tuftsin receptors and later mapped to Nrp1 (Neuropilin-1) and other components.
Beyond its immunological activity, tuftsin has been reported to have effects on CNS endpoints, providing the biological rationale for using stabilised tuftsin analogs as research tools in behavioural neuropharmacology. Native tuftsin is rapidly cleaved in vivo, so extended-half-life analogs are needed for practical experimental use.
The Selank design
Selank was designed as a stabilised heptapeptide with the native tuftsin sequence Thr-Lys-Pro-Arg at the N-terminus and a Pro-Gly-Pro C-terminal extension that dramatically improves resistance to enzymatic cleavage. The Pro-Gly-Pro tail is itself a stable peptide motif with independent biological activity in some Russian pharmacology literature, but its role in Selank is primarily half-life extension.
The result is a synthetic peptide with the tuftsin pharmacophore preserved for receptor engagement but with a plasma half-life sufficient for animal-model studies with practical exposure intervals. Selank is one of a broader family of Pro-Gly-Pro-extended analogs developed in the same research program, including Semax (an ACTH(4-7) analog with the same stabilising tail).
Preclinical characterisation: anxiolytic and cognitive endpoints
The most-cited preclinical work on Selank characterises anxiolytic-like activity in rodent behavioural models — elevated-plus-maze, open-field, and social-interaction paradigms — with a profile typically compared against benzodiazepine reference compounds. Reported endpoints include reduced anxiety-like behaviour without sedation or motor impairment.
Cognitive endpoints have been characterised in learning and memory paradigms, with reports of positive effects on retention and reversal learning in rodent models. The mechanistic connection between anxiolytic and cognitive effects has been framed variously through neurotransmitter modulation, immune signalling, and BDNF-related pathways in the Russian preclinical literature.
Proposed mechanisms
The mechanistic framework for Selank remains an active area of the literature. Several arms have been proposed and are supported to varying degrees by preclinical data: modulation of GABAergic signalling (relevant to the anxiolytic profile), modulation of enkephalinase activity leading to elevated endogenous enkephalin tone, effects on serotonin and dopamine turnover in specific brain regions, and immune-signalling effects consistent with the tuftsin lineage of the pharmacophore.
No single mechanism is universally accepted as primary. This is not unusual for a small peptide with modest receptor selectivity and broad reported activity across endpoints — the mechanistic picture takes decades to consolidate, and much of the definitive comparative work is still to be done for Selank in particular.
Comparative context: Selank, Semax, and tuftsin
Within the Pro-Gly-Pro-stabilised Russian peptide family, Selank is most often discussed alongside Semax (an ACTH(4-7) analog with the same Pro-Gly-Pro extension). Semax carries an ACTH-derived rather than tuftsin-derived N-terminal pharmacophore and has been characterised primarily in cognitive and neuroprotection endpoints.
Comparing Selank to native tuftsin illustrates the practical value of the Pro-Gly-Pro tail: same core pharmacophore, dramatically improved half-life, and an experimental object suited to animal-model work with realistic study timelines.
Analytical characterisation
Selank is characterised by reversed-phase HPLC for purity and mass spectrometry for identity. As a 7-residue peptide with a molecular weight near 751 Da, standard peptide-characterisation methods are directly applicable.
Chromatographic conditions should be tuned to resolve related fragment impurities. A batch COA should include HPLC purity, mass-spec identity, and — where relevant — assessment of related peptide impurities that could arise from partial synthesis or degradation.
Reconstitution and storage
Lyophilised Selank is soluble in aqueous buffer and reconstituted with bacteriostatic or sterile water. As a linear peptide without disulfide bridges or unusual chemistries, its stability profile is broadly consistent with other similarly-sized research peptides.
Store lyophilised material sealed and cold; aliquot reconstituted material into single-use portions. Working-concentration stability in solution should be characterised in the specific buffer system used.
Worked examples
Reconstituting a 5 mg Selank vial
- 01Bring the sealed vial to room temperature.
- 02Wipe the stopper with an alcohol swab.
- 03Add 2.5 mL of bacteriostatic water for a nominal 2 mg/mL working concentration.
- 04Let the diluent run down the inside wall of the vial. Do not spray onto the solid.
- 05Swirl gently until dissolved.
- 06Label with lot, concentration, diluent, and reconstitution date.
Storage protocol
- 01Lyophilised material: sealed and desiccated at 2–8 °C short-term or −20 °C long-term.
- 02Reconstituted material: refrigerated at 2–8 °C, aliquotted into single-use portions.
- 03Track freeze-thaw cycles per aliquot.
Frequently asked questions
What is Selank derived from?
Selank is a synthetic heptapeptide with the endogenous tuftsin tetrapeptide (Thr-Lys-Pro-Arg) at the N-terminus and a Pro-Gly-Pro C-terminal extension for stability. It preserves the tuftsin pharmacophore while dramatically improving in-vivo half-life.
How does Selank differ from Semax?
Both are Pro-Gly-Pro-extended stabilised peptides from the same Russian research program. Selank carries the tuftsin (Thr-Lys-Pro-Arg) pharmacophore; Semax carries the ACTH(4-7) pharmacophore. They engage different upstream receptor systems while sharing the stabilising tail design.
What preclinical endpoints has Selank been characterised in?
Anxiolytic-like activity in rodent behavioural models (elevated-plus-maze, open-field, social-interaction), cognitive endpoints in learning and memory paradigms, and immune-signalling effects consistent with the tuftsin lineage.
What analytical tests confirm identity and purity?
Reversed-phase HPLC quantifies purity; mass spectrometry confirms identity against the expected molecular weight near 751 Da. A batch COA should include both.
How should reconstituted Selank be stored?
Refrigerated at 2–8 °C, aliquotted into single-use portions to minimise freeze-thaw exposure.
References
Selected published research referenced in this article.
- 01Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neurosci Med. 2013;4:223–252.
- 02Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38–48. PubMed
- 03Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(9):855–860. PubMed
- 04Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskii II, Zakharova NM, Kondrashova MN. Neuroprotective effect of pharmacological preconditioning with Selank on the model of transient ischemia in rats. Bull Exp Biol Med. 2010;149(4):428–430. PubMed
- 05Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. PubMed
- 06Najjar VA. Biological effects of tuftsin and its analogs. Drugs Today (Barc). 2011;47(8):595–612. PubMed